Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
According to the FDA, there is no longer a shortage of semaglutide, the active ingredient in the wildly popular Ozempic and Wegovy — a very bad omen for the countless telehealth and pharmacy ...